Streetbeat News

Analyst Ratings

CORT

Truist Securities has maintained a Buy rating on Corcept Therapeutics and raised the price target from $65 to $76, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:09 pm

COP

Truist Securities has maintained a Buy rating on ConocoPhillips but lowered the price target from $145 to $138.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:05 pm

LUNR

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Intuitive Machines (NASDAQ:LUNR) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:05 pm

LILM

Cantor Fitzgerald analyst Andres Sheppard has reiterated an Overweight rating on Lilium (NASDAQ:LILM) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:03 pm

CRK

Truist Securities has maintained a Hold rating on Comstock Resources (NYSE:CRK) while raising the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:02 pm

LCID

Cantor Fitzgerald analyst Andres Sheppard has reiterated a Neutral rating on Lucid Group (NASDAQ:LCID) and maintained a $4 price target.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:01 pm

BEP

UBS analyst William Grippin has upgraded Brookfield Renewable (NYSE:BEP) from Neutral to Buy and increased the price target from $24 to $31.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 2:01 pm

CHTR

Analysts have mixed ratings for Charter Communications (NASDAQ:CHTR), with a range of bullish to bearish sentiments. The average 12-month price target has increased by 11.64% to $354.93. Charter's financials show strong revenue growth and ROE, but challenges with net margin and high debt levels.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 2:00 pm

VIRT

Analysts have provided mixed ratings for Virtu Financial (NASDAQ:VIRT) over the past three months, with a range of price targets indicating potential growth. The company's financial performance shows strong revenue growth but challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 2:00 pm

OPCH

Analysts have recently evaluated Option Care Health (NASDAQ:OPCH), providing a range of ratings from somewhat bullish to neutral. The average 12-month price target has increased slightly to $37.75. The company shows strong financial health with notable revenue growth and efficient cost management.

Portfolio Pulse from Benzinga Insights

September 30, 2024 | 2:00 pm